• Hutchison MediPharma Ltd., of London, began a Phase I trial of theliatinib (HMPL-309) in advanced solid tumors. The objectives of the study are safety and tolerability, as well as determining the maximum tolerated dose. Efficacy against non-small-cell lung cancer and pharmacokinetics also will be evaluated. Theliatinib is an inhibitor of epidermal growth factor receptor (EGFR) that has shown strong antitumor activity against EGFR wild-type tumors in preclinical studies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter